Dr Reddys Laboratories

Dr. Reddy's Laboratories, an India-headquartered Pharmaceutical Preparation Manufacturing company, reported its most recent Scope 1 emissions as 142,772,000 kg CO2e for 2025. Scope 2 emissions (market-based) were 94,690,000 kg CO2e, and Scope 3 emissions were 845,849,000 kg CO2e for the same year.

Looking back, in 2024, the company's Scope 1 emissions were 189,530,000 kg CO2e, Scope 2 emissions were 114,655,000 kg CO2e, and Scope 3 emissions were 866,992,000 kg CO2e. In 2023, Dr. Reddy's Laboratories' Scope 1 emissions were 214,257,000 kg CO2e, Scope 2 emissions were 137,627,000 kg CO2e, and Scope 3 emissions were 921,055,000 kg CO2e.

Dr. Reddy's Laboratories has set ambitious climate commitments. The company aims to achieve net-zero greenhouse gas emissions across its entire value chain by FY2045. As part of its near-term targets, the company commits to reducing absolute Scope 1 and 2 GHG emissions by 80.0% by FY2030 from a FY2023 base year. Additionally, it aims to reduce Scope 3 GHG emissions by 51.6% per INR value added within the same timeframe, covering categories such as purchased goods and services, capital goods, and upstream and downstream transportation.

For long-term targets, Dr. Reddy's Laboratories commits to a 90.0% reduction in absolute Scope 1 and 2 GHG emissions by FY2045 from a FY2023 base year. Similarly, it aims to reduce absolute Scope 3 GHG emissions by 90.0% by FY2045 from a FY2023 base year, encompassing a wide range of categories. These targets have been validated by the Science Based Targets initiative (SBTi) and are consistent with reductions required to keep warming to 1.5°C. The company also has a goal of achieving 100% renewable power by 2030.